Ann. Oncol.

ISSN	1569-8041
ISSN-L	0923-7534
IUID	71283ed43c26433292e1c71865bdb106
Modified	2020-11-27T13:12:55.859Z
Created	2018-12-05T09:48:04.839Z

Year 2022

PubMed DOI Crossref

The age-dependent association of risk factors with pancreatic cancer.

Yuan C, Kim J, Wang QL, ..., Kraft P, Wolpin BM

Ann. Oncol. 33 (7) 693-701 [2022-07-00; online 2022-04-06]

DDLS Fellow Qiaoli Wang

Year 2021

PubMed DOI Crossref

Genomic testing for targeted oncology drugs: hopes against hype.

Dienstmann R, Tamborero D

Ann. Oncol. 32 (7) 837-838 [2021-07-00; online 2021-05-13]

Year 2020

PubMed DOI Crossref

Managing COVID-19 in the oncology clinic and avoiding the distraction effect.

Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T

Ann. Oncol. 31 (5) 553-555 [2020-05-00; online 2020-03-19]

PubMed DOI Crossref

Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles.

Helleday T

Ann. Oncol. 31 (2) 167-168 [2020-02-00; online 2020-01-22]

Year 2019

PubMed DOI Crossref

Making immunotherapy 'cold' tumours 'hot' by chemotherapy-induced mutations-a misconception.

Helleday T

Ann. Oncol. 30 (3) 360-361 [2019-03-01; online 2019-01-31]

Year 2018

PubMed DOI Crossref

Different menopausal hormone regimens and risk of breast cancer.

Brusselaers N, Tamimi RM, Konings P, ..., Adami HO, Lagergren J

Ann. Oncol. 29 (8) 1771-1776 [2018-08-01; online 2018-06-20]

Affiliated researcher

PubMed DOI Crossref

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.

Venkatesan S, Rosenthal R, Kanu N, ..., Harris RS, Swanton C

Ann. Oncol. 29 (3) 563-572 [2018-03-01; online 2018-01-13]

Affiliated researcher

Year 2017

PubMed DOI Crossref

Chemotherapy-induced toxicity-a secondary effect caused by released DNA?

Helleday T

Ann. Oncol. 28 (9) 2054-2055 [2017-09-01; online 2017-09-16]

PubMed DOI Crossref

CHD1: a new treatment biomarker for recombination deficiency in castration resistant prostate cancer?

Helleday T

Ann. Oncol. 28 (7) 1407-1408 [2017-07-01; online 2017-04-14]

Year 2016

PubMed DOI Crossref

Validation and development of MTH1 inhibitors for treatment of cancer.

Warpman Berglund U, Sanjiv K, Gad H, ..., Scobie M, Helleday T

Ann. Oncol. 27 (12) 2275-2283 [2016-12-00; online 2016-11-08]

Affiliated researcher

PubMed DOI Crossref

PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.

Helleday T

Ann. Oncol. 27 (5) 755-757 [2016-05-00; online 2016-02-09]

PubMed DOI Crossref

Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.

Sand M, Bechara FG, Gambichler T, ..., Schnabel R, Hessam S

Ann. Oncol. 27 (2) 332-338 [2016-02-00; online 2015-11-16]

Affiliated researcher Marc Friedländer SciLifeLab Fellow

Year 2014

PubMed DOI Crossref

Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival.

Helleday T

Ann. Oncol. 25 (7) 1253-1255 [2014-07-00; online 2014-04-15]